دورية أكاديمية
أعرض في EDS

Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma.

التفاصيل البيبلوغرافية
العنوان: Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma.
المؤلفون: Valdez CN; School of Medicine, Yale University, New Haven, CT 06520, USA., Sánchez-Zuno GA; Department of Medicine, Section of Rheumatology, Allergy and Immunology, Yale University, New Haven, CT 06520, USA., Osmani L; Department of Medicine, Section of Rheumatology, Allergy and Immunology, Yale University, New Haven, CT 06520, USA., Ibrahim W; Department of Dermatology, Yale University, New Haven, CT 06520, USA., Galan A; Department of Dermatology, Yale University, New Haven, CT 06520, USA., Bacchiocchi A; Department of Dermatology, Yale University, New Haven, CT 06520, USA., Halaban R; Department of Dermatology, Yale University, New Haven, CT 06520, USA., Kulkarni RP; Department of Dermatology, Oregon Health and Science University, Portland, OR 97239, USA.; Cancer Early Detection Advanced Research Center (CEDAR), Portland, OR 97239, USA.; Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA.; Department of Veterans Affairs Portland Health Care System, Operative Care Division, U.S. Portland, OR 97239, USA., Kang I; School of Medicine, Yale University, New Haven, CT 06520, USA.; Department of Medicine, Section of Rheumatology, Allergy and Immunology, Yale University, New Haven, CT 06520, USA., Bucala R; School of Medicine, Yale University, New Haven, CT 06520, USA.; Department of Medicine, Section of Rheumatology, Allergy and Immunology, Yale University, New Haven, CT 06520, USA.; Yale Cancer Center, Yale University, New Haven, CT 06520, USA., Tran T; School of Medicine, Yale University, New Haven, CT 06520, USA.; Department of Medicine, Section of Medical Oncology, Yale University, New Haven, CT 06520, USA.; Yale Cancer Center, Yale University, New Haven, CT 06520, USA.
المصدر: Oncotarget [Oncotarget] 2024 Jul 19; Vol. 15, pp. 507-520. Date of Electronic Publication: 2024 Jul 19.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: Electronic Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Albany, N.Y. : Impact Journals
مواضيع طبية MeSH: Macrophage Migration-Inhibitory Factors*/metabolism , Macrophage Migration-Inhibitory Factors*/genetics , Melanoma*/drug therapy , Melanoma*/genetics , Melanoma*/metabolism , Melanoma*/pathology , Melanoma*/mortality , Intramolecular Oxidoreductases*/genetics , Intramolecular Oxidoreductases*/metabolism , Antigens, Differentiation, B-Lymphocyte*/metabolism , Antigens, Differentiation, B-Lymphocyte*/genetics , Histocompatibility Antigens Class II*/genetics , Histocompatibility Antigens Class II*/metabolism , Biomarkers, Tumor*/metabolism , Biomarkers, Tumor*/genetics, Humans ; Prognosis ; Male ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Adult ; Skin Neoplasms/drug therapy ; Skin Neoplasms/genetics ; Skin Neoplasms/pathology ; Skin Neoplasms/metabolism ; Skin Neoplasms/mortality ; Mutation ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Inhibitors/pharmacology ; Aged, 80 and over
مستخلص: Macrophage Migration Inhibitory Factor (MIF) and its homolog D-dopachrome Tautomerase (DDT) have been implicated as drivers of tumor progression across a variety of cancers. Recent evidence suggests MIF as a therapeutic target in immune checkpoint inhibition (ICI) resistant melanomas, however clinical evidence of MIF and particularly of DDT remain limited. This retrospective study analyzed 97 patients treated at Yale for melanoma between 2002-2020. Bulk-RNA sequencing of patient tumor samples from the Skin Cancer SPORE Biorepository was used to evaluate for differential gene expression of MIF, DDT, CD74, and selected inflammatory markers, and gene expression was correlated with patient survival outcomes. Our findings revealed a strong correlation between MIF and DDT levels, with no statistically significant difference across common melanoma mutations and subtypes. Improved survival was associated with lower MIF and DDT levels and higher CD74:MIF and CD74:DDT levels. High CD74:DDT and CD74:MIF levels were also associated with enrichment of infiltrating inflammatory cell markers. These data suggest DDT as a novel target in immune therapy. Dual MIF and DDT blockade may provide synergistic responses in patients with melanoma, irrespective of common mutations, and may overcome ICI resistance. These markers may also provide prognostic value for further biomarker development.
References: Clin Cancer Res. 2016 Jun 15;22(12):3016-24. (PMID: 26783288)
J Immunol. 1996 Apr 15;156(8):2667-73. (PMID: 8609381)
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592. (PMID: 36300620)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Elife. 2022 Jul 27;11:. (PMID: 35894206)
N Engl J Med. 2017 Nov 9;377(19):1824-1835. (PMID: 28891423)
Hepatology. 2014 Feb;59(2):580-91. (PMID: 23913513)
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. (PMID: 38230766)
Pathol Oncol Res. 2017 Apr;23(2):235-244. (PMID: 27771887)
Protein Sci. 2019 Nov;28(11):1947-1951. (PMID: 31441146)
Front Immunol. 2020 Nov 25;11:609948. (PMID: 33324425)
N Engl J Med. 2018 Aug 23;379(8):722-730. (PMID: 30134131)
J Thorac Dis. 2020 Nov;12(11):7032-7038. (PMID: 33282408)
Bioinformatics. 2019 Jul 15;35(14):i436-i445. (PMID: 31510660)
Cancers (Basel). 2021 Nov 13;13(22):. (PMID: 34830841)
Cell Mol Life Sci. 2022 Jan 29;79(2):105. (PMID: 35091838)
Br J Cancer. 2012 Oct 23;107(9):1498-505. (PMID: 22955855)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Expert Opin Ther Targets. 2019 Sep;23(9):733-744. (PMID: 31414920)
Cancers (Basel). 2020 Dec 09;12(12):. (PMID: 33317028)
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):E577-85. (PMID: 21817065)
OMICS. 2012 May;16(5):284-7. (PMID: 22455463)
Eur J Cancer. 2016 Feb;54:139-148. (PMID: 26765102)
N Engl J Med. 2021 Jun 10;384(23):2229-2240. (PMID: 34107182)
Cancers (Basel). 2020 Sep 30;12(10):. (PMID: 33008022)
Cell Signal. 2019 May;57:76-88. (PMID: 30682543)
Invest Ophthalmol Vis Sci. 1997 May;38(6):1277-82. (PMID: 9152248)
Drug Discov Today. 2018 Nov;23(11):1910-1918. (PMID: 29936245)
Lancet. 2021 Sep 11;398(10304):1002-1014. (PMID: 34509219)
Clin Cancer Res. 2019 Sep 1;25(17):5191-5201. (PMID: 30923036)
N Engl J Med. 2018 May 10;378(19):1789-1801. (PMID: 29658430)
Cell Death Dis. 2022 Feb 4;13(2):117. (PMID: 35121729)
Science. 1966 Jul 1;153(3731):80-2. (PMID: 5938421)
Cell Syst. 2015 Dec 23;1(6):417-425. (PMID: 26771021)
J Pathol. 2023 Jan;259(1):46-55. (PMID: 36214539)
Nat Rev Rheumatol. 2019 Jul;15(7):427-437. (PMID: 31197253)
Bioinformatics. 2013 Jul 15;29(14):1830-1. (PMID: 23740750)
Inflamm Res. 2017 Mar;66(3):209-216. (PMID: 27752708)
Curr Mol Med. 2023 Oct 03;:. (PMID: 37807647)
Proc Natl Acad Sci U S A. 1966 Jul;56(1):72-7. (PMID: 5229858)
Front Immunol. 2018 May 23;9:1132. (PMID: 29875777)
Oncogene. 2017 Jun 29;36(26):3749-3759. (PMID: 28218903)
Cancers (Basel). 2023 Jan 06;15(2):. (PMID: 36672343)
J Cell Mol Med. 2017 Jan;21(1):35-45. (PMID: 27605340)
Methods Mol Biol. 2018;1711:243-259. (PMID: 29344893)
Biochem Biophys Res Commun. 1999 Nov 2;264(3):751-8. (PMID: 10544003)
Cell Death Dis. 2023 Sep 4;14(9):587. (PMID: 37666813)
Curr Oncol Rep. 2023 Sep;25(9):989-996. (PMID: 37266890)
Cancers (Basel). 2023 Feb 09;15(4):. (PMID: 36831449)
J Exp Clin Cancer Res. 2022 Oct 14;41(1):303. (PMID: 36242053)
Nucleic Acids Res. 2000 Jan 1;28(1):27-30. (PMID: 10592173)
Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204)
FASEB J. 2021 May;35(5):e21418. (PMID: 33774873)
Front Immunol. 2020 Jun 18;11:1191. (PMID: 32625208)
J Immunol. 2013 Mar 15;190(6):2984-93. (PMID: 23390297)
Nat Rev Rheumatol. 2022 Nov;18(11):641-656. (PMID: 36198831)
Oncotarget. 2014 Jan 15;5(1):103-7. (PMID: 24406307)
Oncoimmunology. 2020 Dec 6;9(1):1846915. (PMID: 33344042)
Int J Mol Sci. 2024 Apr 29;25(9):. (PMID: 38732068)
Cancer Treat Rev. 2017 Mar;54:34-42. (PMID: 28189914)
معلومات مُعتمدة: P50 CA121974 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: DDT; MIF; cancer transcriptomics; immune checkpoint inhibition; melanoma
المشرفين على المادة: 0 (Macrophage Migration-Inhibitory Factors)
EC 5.3.- (Intramolecular Oxidoreductases)
0 (Antigens, Differentiation, B-Lymphocyte)
0 (invariant chain)
0 (Histocompatibility Antigens Class II)
EC 5.3.3.12 (dopachrome isomerase)
EC 5.3.2.1 (MIF protein, human)
0 (Biomarkers, Tumor)
0 (Immune Checkpoint Inhibitors)
تواريخ الأحداث: Date Created: 20240719 Date Completed: 20240719 Latest Revision: 20240802
رمز التحديث: 20240802
مُعرف محوري في PubMed: PMC11259151
DOI: 10.18632/oncotarget.28615
PMID: 39028303
قاعدة البيانات: MEDLINE
الوصف
تدمد:1949-2553
DOI:10.18632/oncotarget.28615